A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors

Limited therapeutic options exist for the treatment of patients with triple negative breast cancer (TNBC). Neoadjuvant chemotherapy is currently the standard of care treatment in the early stages of the disease, although reliable biomarkers of response have been scarcely described. In our study we e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Immunol
Main Authors: Pérez-Pena, Javier, Tibor Fekete, Janos, Páez, Raquel, Baliu-Piqué, Mariona, García-Saenz, José Ángel, García-Barberán, Vanesa, Manzano, Aránzazu, Pérez-Segura, Pedro, Esparis-Ogando, Azucena, Pandiella, Atanasio, Gyorffy, Balázs, Ocana, Alberto
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019
Assuntos:
Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6930158/
https://ncbi.nlm.nih.gov/pubmed/31921107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.02802
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados